The ANK1 Knockout A-549 Polyclonal Cells comprise a polyclonal population of A-549 cells engineered via CRISPR/Cas9-mediated disruption of the ANK1 gene, encoding the scaffold protein ankyrin-1. This product provides a pooled knockout model, derived without single-cell cloning, enabling researchers to study the collective functional consequences of ANK1 loss in a heterogeneous cell population. The knockout strategy generates a mixed population harboring various loss-of-function alleles, offering a robust system for investigating gene function in a physiologically relevant context. This polyclonal knockout product is designed for applications requiring a genetically diverse knockout pool, minimizing clonal artifacts and allowing assessment of phenotypic variability.
The parental A-549 cell line is a well-characterized model derived from human lung adenocarcinoma epithelial cells, originally isolated from a 58-year-old Caucasian male with lung carcinoma. A-549 cells are widely employed in cancer biology and respiratory research due to their retention of key epithelial features and their utility in studying oncogenic signaling, drug responses, and metastatic mechanisms. These adherent cells exhibit a stable genotype and are permissive for studies of cell adhesion, migration, and cytoskeletal organization, making them an ideal host for interrogating genes involved in tumor progression. The A-549 background provides a clinically relevant lung cancer model for dissecting the role of ankyrin-1 in adenocarcinoma pathophysiology.
ANK1 encodes ankyrin-1, a spectrin-binding scaffold protein that anchors integral membrane proteins, including Na+/K+ ATPase, anion exchanger 1 (SLC4A1), CD44, and L1CAM, to the underlying spectrin-actin cytoskeleton. Ankyrin-1 is regulated by upstream kinases such as cAMP-dependent protein kinase (PKA) and protein kinase C (PKC), and by calcium-dependent proteases including calpain. Through its interactions with spectrin (SPTAN1, SPTBN1), actin, and the IP3 receptor, ANK1 orchestrates membrane domain stability and ion transport. The mechanistic summary provided indicates that knockout of ANK1 disrupts these anchoring interactions, compromising cytoskeletal integrity and altering the trafficking and function of associated membrane proteins. This signaling network positions ANK1 as a critical hub in cellular architecture and signal transduction.
In A-549 lung adenocarcinoma cells, disruption of ANK1 yields a valuable model for studying the interplay between cytoskeletal organization and cancer cell behavior. Loss of ankyrin-1 is predicted to perturb cell adhesion, migration, and ion homeostasis, processes intimately linked to tumor invasion and metastasis. The polyclonal knockout pool allows researchers to evaluate how heterogeneous ANK1 deficiency affects the epithelial-mesenchymal transition (EMT) and metastatic potential in a lung cancer context. By uncoupling membrane proteins from the spectrin-actin network, this model facilitates investigation of how cytoskeletal defects contribute to oncogenic transformation and malignant progression, offering insights into potential therapeutic vulnerabilities in lung adenocarcinoma.
This ANK1 knockout product supports a broad range of experimental applications, including cancer cell biology, cytoskeletal dynamics, cell adhesion and migration assays, and drug target validation. Representative assays include Western blotting and RT-qPCR for confirming ANK1 disruption, immunofluorescence to visualize cytoskeletal and membrane protein mislocalization, and cell migration and invasion assays to assess metastatic behavior. Co-immunoprecipitation studies can probe altered protein interactions, while flow cytometry monitors surface receptor expression. Additional applications encompass drug sensitivity profiling, apoptosis assays, and phospho-signaling analyses to map downstream pathways. For further details or inquiries, please contact Ascent Research.
